UNSPSC 51263125: Levobunolol

This classification denotes a beta-adrenergic blocking agent and anti-glaucoma agent with the molecular formula C17H25NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G6317AOI7K, chemically known as 3,4-dihydro-5-(3-(tert-butylamino)-2-hydroxy)propoxy-1(2h)-naphthalenone but generally known as levobunolol, which bears US NIH Compound Identifier 3914. European Medicines Agency schedules Levobunolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08463MIG.

UNSPSC 51263125 Levobunolol is a Commodity code that nominally describes a specific ophthalmic beta-blocker medication, but recent state and local procurement activity under this code shows minimal alignment with the code's stated scope. The single concrete opportunity posted under this code—Seminole County, Florida's IFB for Naloxone and Safe Drug Deactivation Systems—involves entirely different pharmaceutical products (an opioid antagonist and drug disposal systems) with no connection to levobunolol's therapeutic class or clinical use. A second opportunity tagged to the code, the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs, addresses pharmacy benefit program structure and contracting models rather than specific pharmaceutical procurement. State and local governments do not appear to be soliciting levobunolol supplies under this code with any regularity.

The Seminole County opportunity (IFB 60459723LAS, due July 26, 2023) represents the only concrete product procurement in the recent block, seeking annual delivery of 1,900 units of naloxone and 800 drug deactivation systems to a county health facility with quarterly shipments and fixed pricing. The Texas HHS RFI (posted April 3, 2026) is exploratory market intelligence gathering, not a transactional procurement. The code shows activity in Florida and Texas, but geographic coverage is too narrow and opportunity volume too sparse to support a meaningful strategy. The mismatch between the code's nominal scope and actual solicitation content suggests either tagging error in the county's or state's procurement database or that levobunolol itself sees negligible state and local demand. Vendors pursuing work under this code should verify that opportunities are genuinely pharmaceutical product procurements rather than relying on the UNSPSC tag alone.